News Conference News ACC 2025 By 2 Years, Tricuspid TEER Reduces Hospitalizations for HF: TRILUMINATE Michael O'Riordan March 31, 2025
News Conference News ACC 2025 Evolut Low Risk Trial: TAVI Holds Up to Surgery at 5 Years L.A. McKeown March 30, 2025
News Conference News ACC 2025 Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI Caitlin E. Cox March 30, 2025
Presentation ACC 2025 Two-year Outcomes Of Transcatheter Tricuspid Valve Edge-to-Edge Repair For Tricuspid Regurgitation: The TRILUMINATE Pivotal Trial Presenter: Saibal Kar March 30, 2025
Presentation ACC 2025 Dapagliflozin after Transcatheter Aortic Valve Implantation Presenter: Sergio Raposeiras-Roubin March 29, 2025
News Opinion Editor's Corner ACC 2025 What’s Going to Be Hot at ACC 2025? Michael O'Riordan March 26, 2025